Señales en vivo de REDX.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 12:28):

Stats
Volumen de hoy	6.64M
Volumen promedio	966 377
Capitalización de mercado	58.35M
EPS	£0 ( 2023-12-14 )
Próxima fecha de ganancias	( £0 ) 2024-05-06
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.500
ATR14	£1.467 (10.76%)

Volumen Correlación

Largo: -0.05 (neutral)

Corto: 0.62 (weak)

Signal:(45.884) Neutral

Redx Pharma PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Redx Pharma PLC Correlación - Moneda/Commodity

0.19
( neutral )

0.36
( neutral )

-0.26
( neutral )

0.36
( neutral )

-0.67
( moderate negative )

-0.73
( moderate negative )

Redx Pharma PLC Finanzas

Annual	2023
Ingresos:	£4.20M
Beneficio Bruto:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2023
Ingresos:	£4.20M
Beneficio Bruto:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2022
Ingresos:	£18.69M
Beneficio Bruto:	£18.69M (100.00 %)
EPS:	£-0.0612

FY	2021
Ingresos:	£10.04M
Beneficio Bruto:	£0.00 (0.00 %)
EPS:	£-0.127

Financial Reports:

No articles found.

Redx Pharma PLC

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Actualizaciones en tiempo real para Redx Pharma PLC [REDX.L]

Upcoming Earnings Alert